BCG+MM Trial: Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a 2-stage, randomised phase 3 trial.

点击翻译按钮获取中文摘要

Non-muscle invasive bladder cancer is common, causes substantial suffering and requires radical removal or irradiation of the bladder within 5 years in over 30% of people with high risk tumours despite best current treatment. Preliminary studies show exciting results from adding mitomycin (a chemotherapy drug) to best current treatment with BCG (an immunotherapy). This large randomized trial will determine the effects of adding mitomycin on cure rates, survival, side effects and quality of life.